Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 10Mesothelioma, Malignant 3Solid Tumors 2Advanced Solid Tumors 2Unspecified Childhood Solid Tumor, Protocol Specific 1Mesothelioma 1Advanced or Metastatic Solid Tumors 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Injections 27Carboplatin 18Docetaxel 14pembrolizumab 13Paclitaxel 12Bevacizumab 10durvalumab 8Nivolumab 8Cisplatin 8Fluorouracil 7Pemetrexed 6Oxaliplatin 6Leucovorin 6trifluridine tipiracil drug combination 5toripalimab 5tislelizumab 5linifanib 5Capecitabine 5zimberelimab 4talazoparib 4olaparib 4fludarabine 4Panobinostat 4Itraconazole 4Irinotecan 4Gemcitabine 4Everolimus 4tremelimumab 3sotorasib 3sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Solid Tumors × Bortezomib × Other solid neoplasm × Clear all
NCT02057380 2024-11-20

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Astellas Pharma Inc

Phase 2 Completed
13 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT01497626 2016-02-17

Lapatinib and Bortezomib in Patients With Advanced Malignancies

Georgetown University

Phase 1 Terminated
15 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡